Good morning, you're tuned in to Markets Desk.
Novartis is moving to deepen its oncology footprint, agreeing to acquire UK-based Myricx Bio in a deal valued at up to one point five billion dollars. Myricx is developing a new class of antibody-drug conjugates, and the acquisition signals Novartis is willing to pay a premium to stay competitive in one of pharma's most contested therapeutic arenas.
Turning to media, Comcast is adding a British broadcaster to its portfolio just one week after announcing plans to spin off NBCUniversal. The timing is striking — the Philadelphia conglomerate is simultaneously shedding domestic assets while expanding internationally, a strategic posture that raises real questions about where management sees long-term value in the media landscape.
And in Hong Kong, MiniMax Group founder Yan Junjie is staring down a difficult moment as lockup periods on his AI company's shares expire Wednesday. The stock has already shed thirty-nine billion dollars in market value, and with fresh selling pressure now legally permitted, the question for investors is whether fundamentals can hold the line against what could become a significant overhang.
That's the tape. Markets Desk, signing off the floor.
